Amarin develops generic formulation of Glucotrol XL

Published: 5-Mar-2003

Amarin Corporation's Swedish subsidiary Amarin Development has developed a generic formulation of glipizide extended release tablets, as part of an agreement with Watson Pharmaceuticals.


Amarin Corporation's Swedish subsidiary Amarin Development has developed a generic formulation of glipizide extended release tablets, as part of an agreement with Watson Pharmaceuticals.

Glipizide extended release tablets are marketed in the US under the trade name Glucotrol XL by Pfizer. Watson has filed an Abbreviated New Drug Application (ANDA) with the US FDA, seeking approval to market its generic version of Glucotrol XL tablets 5mg and 10mg.

Glucotrol XL is indicated as an adjunct to diet for the control of hyperglycemia in patients with type-2 diabetes. Pfizer reported US Glucotrol XL sales of approximately US$265m (€241m) for the twelve months to September 30, 2002.

'This collaboration with Watson Pharmaceuticals demonstrates Amarin's capability of developing technically challenging products,' said Rick Stewart, chief executive officer of Amarin. This, together with other collaborations, including one with Tanabe for morphine in Japan, demonstrate the strength of Amarin's product development capability, he added.

Amarin Corporation plans to become a leader in neurology and pain management by providing innovative products and solutions that address significant unmet medical needs. The company has 11 pharmaceutical products on the US market along with a de-velopment pipeline that includes two late-stage candidates: Zelapar (selegiline orally disintegrating tablets), for Parkinson's disease and LAX-101, a proprietary compound for Huntington's Disease.

You may also like